Estimated HCV RNA concentrations of eclipse-phase donations with blip viremia infused into chimp X331 (experiment II, phase 2)
| Donor/donation no. . | Days preceding ramp-up* . | No. of TMA-positive replicates (%) . | Imputed HCV RNA copies/mL (95% fiducial limits)† . | Infused HCV RNA copies . |
|---|---|---|---|---|
| 10050-04 | 41 | 6/27 (22) | 2.22 (1.23-3.17) | 111 |
| 10083-02 | 49 | 23/27 (85) | 11.22 (9.35-13.67) | 561 |
| 10011-02 | 49 | 2/27 (7) | 1.18 (0.53-1.91) | 60 |
| 10029-01 | 48 | 10/27 (38) | 3.37 (2.15-4.47) | 185 |
| 10085-02 | 49 | 10/27 (37) | 3.29 (2.08-4.38) | 164 |
| Donor/donation no. . | Days preceding ramp-up* . | No. of TMA-positive replicates (%) . | Imputed HCV RNA copies/mL (95% fiducial limits)† . | Infused HCV RNA copies . |
|---|---|---|---|---|
| 10050-04 | 41 | 6/27 (22) | 2.22 (1.23-3.17) | 111 |
| 10083-02 | 49 | 23/27 (85) | 11.22 (9.35-13.67) | 561 |
| 10011-02 | 49 | 2/27 (7) | 1.18 (0.53-1.91) | 60 |
| 10029-01 | 48 | 10/27 (38) | 3.37 (2.15-4.47) | 185 |
| 10085-02 | 49 | 10/27 (37) | 3.29 (2.08-4.38) | 164 |
TMA indicates transcription-mediated amplification.
Plasma from HCV RNA-negative donations from each of these five donors were previously infused into chimp X331 and resulted in no evidence of HCV infection. These donations were collected prior to ramp-up viremia at days −31, −23, −19, −21, and −18, respectively.
RNA copy levels were estimated from probit analysis of replicate testing of the HCV WHO International Standard (NIBSC Codes: 97/690); copies per milliliter were based on a conversion factor of 3.4 RNA copies/IU.